A Phase 3 interventional study of vatreptacog alfa (activated) and eptacog alfa (activated) in Congenital Bleeding Disorder, Haemophilia A With Inhibitors and Haemophilia B With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 32 sites in 19 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2011, is one of 5 in phase 3, and was the 8th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
American Thrombosis and Hemostasis Network · Sites in United States
Ages 12–100
By country, each count listing its studies:
recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2011.
This study's enrollment of 72 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 24 across the 19 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
92 studies in Hemophilia A by Novo Nordisk A/S: 8 open now, 12 under way, 5 of them phase 3. Of 78 finished, 20 (26%) have results posted.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 16th largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2011, is one of 21 in phase 3, and was the 26th registered.
Novo Nordisk A/S’s Hemophilia A studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 92 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.
Scheduled dose visit in a non-bleeding state. Single dose of NNC 0078-0000-0007 (vatreptocog alfa (activated)) every 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: eptacog alfa (activated)
Drug: vatreptacog alfa (activated)
1-3 doses per bleeding episode
1-3 doses per bleeding episode
Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given
Time frame: Within 12 hours of first trial product administration
Effective and Sustained Bleeding Control
Time frame: Up to 48 hours after first trial product administration
Number of Doses of Trial Product Given for Each Acute Bleed
Time frame: Up to 6 hours after first trial product administration
Number of Adverse Events
Any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Adverse events were captured from the time of consent to 1 month (+14 days) after last administration of trial product.
Immunogenicity (Inhibitor Development)
Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or FVII. Radioimmunoassay using \[125I\]-labelled vatreptacog alfa or rFVIIa was used to screen plasma samples for development of anti-drug antibodies
Time frame: Adverse events were captured from the time of consent to the end of trial visit 1 month (+14 days) after last administration of trial product.
Patients treated with vatreptacog alfa were recruited from a total of 46 sites globally in 18 countries, including Austria, Brazil, Croatia, Greece, Hungary, Italy, Japan, Malaysia, Poland, Romania, Russia, Serbia, South Africa, Taiwan, Thailand, Turkey, United Kingdom and United States of America.
| Milestone | Vatreptacog Alfa and rFVIIa (All Subjects) |
|---|---|
| Started | 72 |
| Completed | 64 |
| Not completed | 8 |
| Withdrew: Adverse event | 2 |
| Withdrew: Non-compliance | 2 |
| Withdrew: Withdrawal criteria | 3 |
| Withdrew: Unclassified | 1 |
| bleeding episodes | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| Additional haemostatic given | 22 | 16 |
| Additional haemostatic not given | 318 | 211 |
| bleeding episodes | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| Additional haemostatic given | 53 | 51 |
| Additional haemostatic not given | 268 | 163 |
| bleeding episodes | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| 1 dose | 51 | 23 |
| 2 doses | 94 | 62 |
| 3 doses | 195 | 142 |
Any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| events | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| All adverse events | 55 | 11 |
| Mild adverse events | 33 | 5 |
| Moderate adverse events | 15 | 2 |
| Severe adverse events | 7 | 4 |
Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or FVII. Radioimmunoassay using \[125I\]-labelled vatreptacog alfa or rFVIIa was used to screen plasma samples for development of anti-drug antibodies
| Subjects | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| Positive for anti-vatreptacog alfa | 8 | 0 |
| Cross-reactive with rFVIIa | 4 | 0 |
| Positive for anti-rFVIIa | 0 | 1 |
| In vitro vatreptacog alfa-neutralising | 1 | 0 |
| In vitro FVII/rFVIIa-neutralising | 0 | 0 |
Collected over Adverse events were captured from the time of consent to 1 month (+14 days) after last administration of trial product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vatreptacog Alfa 80 µg/kg | — | 4/72 (5.6%) | 5/72 (6.9%) |
| rFVIIa 90 µg/kg | — | 4/57 (7%) | 3/57 (5.3%) |
| Event | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| Retroperitoneal haemorrhageGastrointestinal disorders | 0/72 | 1/57 |
| Small intestinal obstructionGastrointestinal disorders | 0/72 | 1/57 |
| PyelonephritisInfections and infestations | 0/72 | 1/57 |
| Rectal abscessInfections and infestations | 0/72 | 1/57 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 0/72 | 1/57 |
| Dental cariesGastrointestinal disorders | 1/72 | 0/57 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/72 | 0/57 |
| TelangiectasiaSkin and subcutaneous tissue disorders | 1/72 | 0/57 |
| HaematomaVascular disorders | 1/72 | 0/57 |
| Event | Vatreptacog Alfa 80 µg/kg | rFVIIa 90 µg/kg |
|---|---|---|
| Drug specific antibody presentInvestigations | 5/72 | 3/57 |
| Age, Continuous(years) | Vatrepcacog Alfa and rFVIIa |
|---|---|
| Mean | 30.19 ± 13.84 |
| Sex: Female, Male(Participants) | Vatrepcacog Alfa and rFVIIa |
|---|---|
| Female | 0 |
| Male | 72 |
The record gives a start of Jul 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 4 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vatreptacog alfa · Recombinant FVIIa